Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes


Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S
 

To examine pioglitazone as add-on to metformin and insulin secretagogues in patients with type 2 diabetes and inadequate glycaemic control and its effect on glycaemic control, surrogate measures of insulin sensitivity (adiponectin) and beta-cell function (proinsulin/insulin) and fluid retention. (more) 

 


Dorkhan M, Magnusson M, Frid A, et al. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med. 2006;260:125-133. 

Last Modified: 1/17/2013